Trends in breast cancer in the elderly in Denmark, 1980–2012

Jensen, Jeanette Dupont; Cold, Søren; Nielsen, M.; Jylling, Anne Marie Bak; Søe, Katrine Lydolph; Larsen, Lisbeth Aagaard; Ewertz, Marianne

doi:10.3109/0284186x.2015.1115118

Cited by 26 publications

(13 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the oldest age group, this may in part be explained by the fact that not all patients are permanently cured and may die from the disease at an older age. However, the possibility of undertreatment at older ages cannot be excluded . The Danish Breast Cancer Group's treatment protocols did not cover the oldest patients until 2002, and no adjuvant chemotherapy was recommended for patients above 70 years of age before 2007 .…”

Section: Discussionmentioning

confidence: 99%

Prostate and breast cancer in four Nordic countries: A comparison of incidence and mortality trends across countries and age groups 1975–2013

Kvåle

Myklebust

Engholm

et al. 2017

Intl Journal of Cancer

View full text Add to dashboard Cite

In recent decades, management of prostate and breast cancer patients has changed considerably. The purpose of our study is to interpret patterns of prostate and breast cancer incidence and mortality in four Nordic countries across age groups and time periods. Prostate and breast cancer incidence and mortality data (1975-2013) were obtained from the NORDCAN database. Joinpoint regression models were used to identify changes in the trends. A more prominent increase in prostate than breast cancer incidence was observed. From the mid-1990s, mortality rates in patients below 75 years of age have decreased for both cancers in all four countries. The relative decline in breast cancer mortality from 1985-1989 to 2009-2013 were largest in women under 50 years of age, with reductions in mortality rates ranging from 38% in Finland to 55% in Denmark. In the age group 55-74 years, mortality rates for prostate cancer declined more than for breast cancer in all countries except Denmark, ranging from 14% in Denmark to 39% in Norway. The substantial decrease in breast cancer mortality in women below regular screening age and the reductions in mortality from both cancers in Denmark from the mid-1990s are consistent with beneficial contributions from improved treatment besides mammography screening and increased PSA testing. Alongside similar mortality decreases, the larger increases in prostate cancer incidence as compared to breast cancer indicate that a higher proportion of prostate cancer cases are overdiagnosed.

show abstract

Section: Discussionmentioning

confidence: 99%

Prostate and breast cancer in four Nordic countries: A comparison of incidence and mortality trends across countries and age groups 1975–2013

Kvåle

Myklebust

Engholm

et al. 2017

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…The prognosis after breast cancer is determined by patient characteristics, such as age and comorbidities; disease related factors, such as stage of disease; and treatment. Recent data from Denmark demonstrate that the relative survival decreases with age above 70 years [3]. The proportion of patients with comorbidities increases with age from 13% of patients aged 50-59 years to 40% among patients aged 80 years or more [4].…”

Section: Introductionmentioning

confidence: 99%

Adherence to treatment guidelines and survival in older women with early-stage breast cancer in Denmark 2008–2012

et al. 2020

Self Cite

View full text Add to dashboard Cite

Objectives: The aims of this study were to compare patients 70 years or older with younger patients, to examine whether Danish patients with early-stage breast cancer aged 70 years or more received treatment according to guidelines, the reasons for deviating from the guidelines, and to analyze whether such deviations affected survival. Methods: From the Danish Breast Cancer Cooperative Group (DBCG) database we identified 23,247 women diagnosed with early-stage breast cancer in Denmark from 2008 to 2012. 17,391 were aged less than 70 years and 5856 were 70þ years. We reviewed medical charts of 441 patients aged 70þ years from Funen (a region of Denmark) to ascertain whether treatment was given according to the guidelines of DBCG and if not, the reason for deviating. Overall survival was analyzed by Cox proportional hazards models. Results: Up to age 80 years most women (94%) had surgery according to guidelines, decreasing to 41% in women aged 85þ years, the main reason for omitting surgery being patients' requests. Patients with breast cancer over the age of 80 years did not have an excess mortality compared with the general population in Funen. Compared with women who had surgery according to guidelines, women who did not have surgery had a significantly higher risk of dying with a hazard ratio (HR) of 8.38 (95% Confidence Intervals (CI) 4.46-15.8) if they were less than 80 years and HR ¼ 2.56 (95% CI 1.63-4.01) if they were 80 years or more (p ¼ .003 for interaction). Conclusions: Adherence to treatment according to guidelines decreases with increasing age, mainly for patients aged 80þ years. Our results suggest that surgery is important for the survival of patients aged less than 80 years.

show abstract

“…A major subgroup with guideline violations seems to be patients with higher age (20)(21)(22)(23). Several comparable results have demonstrated that higher age remains a barrier to receiving chemotherapy for EBC, as has been shown, for example, in France (24), Denmark (25), Spain (26), and the US (27). In Germany, the most important reason for discouraging patients from undergoing chemotherapy is somatic comorbidities and age > 75 years (19).…”

Section: Discussionmentioning

confidence: 90%

Impact of age on indication for chemotherapy in early breast cancer patients in Germany

Hoffmann¹,

Hennigs²,

Feißt³

et al. 2022

Preprint

View full text Add to dashboard Cite

Purpose: Today, the decision to treat patients with chemotherapy for early breast cancer (EBC) is made based on the patient’s individual risk stratification and tumor biology. In cases with chemotherapy indication, the neoadjuvant application (NACT) is the preferred option in comparison with primary surgery and adjuvant chemotherapy (ACT). Age remains a relevant factor in the decision-making process. The aim of the present study was to illustrate the impact of age on the use of systemic therapy in clinical routine. Methods: The study separately analyzed chemotherapy use among six age cohorts of EBC patients who had been treated at 104 German breast units between January 2008 and December 2017. Results: In total, 124,084 patients were included, 46,279 (37.3%) of whom had received chemotherapy. For 44,765 of these cases, detailed information on treatment was available. Within this cohort, chemotherapy was administered as NACT to 14,783 patients (33.0%) and as ACT to 29,982 (67.0%) patients. Due to the higher prevalence of unfavorable tumor subtypes, younger patients had a higher rate of chemotherapy (≤29y: 74.2%; 30–39y: 71.3%) and a higher proportion of NACT administration (<29y: 66.9%; 30–39y: 56.0%) in comparison with elderly patients, who had lower rates for overall chemotherapy (60–69y: 37.5%; ≥70y: 17.6%) and NACT (60–69y: 25.5%; ≥70y: 22.8%). Pathologic complete response was higher in younger than in older patients (≤ 29y: 30.4% vs. ≥70y: 16.7%), especially for HER2− subtypes. Conclusion: The data from the nationwide German cohort reveal relevant age-dependent discrepancies concerning the use of chemotherapy for EBC. n = 250 words

show abstract

Trends in breast cancer in the elderly in Denmark, 1980–2012

Cited by 26 publications

References 23 publications

Prostate and breast cancer in four Nordic countries: A comparison of incidence and mortality trends across countries and age groups 1975–2013

Prostate and breast cancer in four Nordic countries: A comparison of incidence and mortality trends across countries and age groups 1975–2013

Adherence to treatment guidelines and survival in older women with early-stage breast cancer in Denmark 2008–2012

Impact of age on indication for chemotherapy in early breast cancer patients in Germany

Contact Info

Product

Resources

About